Roivant Sciences (ROIV) Revenue & Revenue Breakdown
Roivant Sciences Revenue Highlights
Latest Revenue (Y)
$124.80M
Latest Revenue (Q)
$55.13M
Main Segment (Y)
Product
Roivant Sciences Revenue by Period
Roivant Sciences Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-03-31 | $124.80M | 103.65% |
2023-03-31 | $61.28M | 10.84% |
2022-03-31 | $55.29M | 132.34% |
2021-03-31 | $23.80M | -64.85% |
2020-03-31 | $67.69M | 2812.61% |
2019-03-31 | $2.32M | - |
Roivant Sciences Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $55.13M | 90.57% |
2024-03-31 | $28.93M | -22.11% |
2023-12-31 | $37.14M | 0.11% |
2023-09-30 | $37.10M | 71.57% |
2023-06-30 | $21.62M | -21.01% |
2023-03-31 | $27.38M | 60.54% |
2022-12-31 | $17.05M | 36.06% |
2022-09-30 | $12.53M | 190.18% |
2022-06-30 | $4.32M | -53.17% |
2022-03-31 | $9.22M | -62.11% |
2021-12-31 | $24.34M | 74.03% |
2021-09-30 | $13.99M | 80.83% |
2021-06-30 | $7.74M | -48.93% |
2021-03-31 | $15.15M | 163.41% |
2020-12-31 | $5.75M | 334.62% |
2020-09-30 | $1.32M | -16.05% |
2020-06-30 | $1.58M | -97.50% |
2020-03-31 | $62.95M | - |
Roivant Sciences Revenue Breakdown
Roivant Sciences Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Mar 24 | Mar 23 |
---|---|---|
Product | $75.06M | $28.01M |
Quarterly Revenue by Product
Product/Service | Dec 23 | Sep 23 | Jun 23 |
---|---|---|---|
Product Revenue, Net | $20.67M | $18.42M | $16.66M |
Roivant Sciences Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BGNE | BeiGene | $2.46B | $929.17M |
APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
ASND | Ascendis Pharma | $266.72M | $95.89M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
ROIV | Roivant Sciences | $124.80M | $55.13M |
KRYS | Krystal Biotech | $50.70M | $70.28M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
RXDX | Prometheus Biosciences | $6.81M | $1.10M |
PLRX | Pliant Therapeutics | $1.58M | - |
LYRA | Lyra Therapeutics | $1.56M | $598.00K |
PHAT | Phathom Pharmaceuticals | $682.00K | $1.91M |
VRDN | Viridian Therapeutics | $314.00K | $72.00K |
CGEM | Cullinan Oncology | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INZY | Inozyme Pharma | - | - |
SNDX | Syndax Pharmaceuticals | - | $3.50M |
AKRO | Akero Therapeutics | - | - |
ROIV Revenue FAQ
What is Roivant Sciences’s yearly revenue?
Roivant Sciences's yearly revenue for 2024 was $124.8M, representing an increase of 103.65% compared to 2023. The company's yearly revenue for 2023 was $61.28M, representing an increase of 10.84% compared to 2022. ROIV's yearly revenue for 2022 was $55.29M, representing an increase of 132.34% compared to 2021.
What is Roivant Sciences’s quarterly revenue?
Roivant Sciences's quarterly revenue for Q1 2025 was $55.13M, a 90.57% increase from the previous quarter (Q4 2024), and a 154.96% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $28.93M, a -22.11% decrease from the previous quarter (Q3 2024), and a 5.68% increase year-over-year (Q4 2023). ROIV's quarterly revenue for Q3 2024 was $37.14M, a 0.11% increase from the previous quarter (Q2 2024), and a 117.80% increase year-over-year (Q3 2023).
What is Roivant Sciences’s revenue growth rate?
Roivant Sciences's revenue growth rate for the last 3 years (2022-2024) was 125.73%, and for the last 5 years (2020-2024) was 84.37%.
What are Roivant Sciences’s revenue streams?
Roivant Sciences's revenue streams in r 24 are Product
What is Roivant Sciences’s main source of revenue?
For the fiscal year ending Mar 24, the largest source of revenue of Roivant Sciences was Product. This segment made a revenue of $75.06M, representing 100.00% of the company's total revenue.